Universität zu Köln

Boettiger, David C., Sabin, Caroline A., Grulich, Andrew, Ryom, Lene, Bonnet, Fabrice, Reiss, Peter, Monforte, Antonella d'arminio, Kirk, Ole, Phillips, Andrew, Bower, Mark ORCID: 0000-0002-4077-6351, Fatkenheuer, Gerd, Lundgren, Jens D. and Law, Matthew (2016). Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? Aids, 30 (10). S. 1629 - 1638. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1473-5571

Full text not available from this repository.

Abstract

Objective: Nelfinavir exhibits potent anticancer properties against a range of tumours. However, in 2006/2007, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons. Design: Observational cohort study. Methods: D:A:D study data was analysed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1 July 2006-30 June 2007. Results: A total of 42 006 individuals (50% white, 73% male) contributed 303 005 person-years of follow-up between 1 January 2004 and 1 February 2014. At study enrolment, median age was 40 [interquartile range (IQR) 33-46] years and 8305 individuals had a history of nelfinavir use [median duration 1.7 (IQR 0.7-3.4) years]. During follow-up, nelfinavir was used by 2476 individuals for a median of 1.7 (IQR 0.7-3.8) years; 1063 were exposed to nelfinavir between 1 July 2006 and 30 June 2007. Overall, 2279 cancers were diagnosed at a rate of 0.75 [95% confidence interval (95% CI) 0.72-0.78] per 100 person-years. Neither greater cumulative exposure to nelfinavir [adjusted risk ratio (aRR) 0.93 for every additional 5 years, 95% CI 0.82-1.06, P=0.26] nor current use of nelfinavir (aRR 0.98 vs other protease inhibitor use, 95% CI 0.68-1.41, P=0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1 July 2006 and 30 June 2007 compared to those receiving other treatment over this period was 1.07 (95% CI 0.78-1.46, P=0.68). Conclusion: Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of February 2014, exposure to the 2006/2007 contamination of nelfinavir does not appear to be associated with increased cancer incidence. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Boettiger, David C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sabin, Caroline A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Grulich, Andrew UNSPECIFIED UNSPECIFIED UNSPECIFIED Ryom, Lene UNSPECIFIED UNSPECIFIED UNSPECIFIED Bonnet, Fabrice UNSPECIFIED UNSPECIFIED UNSPECIFIED Reiss, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Monforte, Antonella d'arminio UNSPECIFIED UNSPECIFIED UNSPECIFIED Kirk, Ole UNSPECIFIED UNSPECIFIED UNSPECIFIED Phillips, Andrew UNSPECIFIED UNSPECIFIED UNSPECIFIED Bower, Mark UNSPECIFIED orcid.org/0000-0002-4077-6351 UNSPECIFIED Fatkenheuer, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Lundgren, Jens D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Law, Matthew UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-272125
DOI:	10.1097/QAD.0000000000001053
Journal or Publication Title:	Aids
Volume:	30
Number:	10
Page Range:	S. 1629 - 1638
Date:	2016
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1473-5571
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROTEASE INHIBITOR NELFINAVIR; COMBINATION ANTIRETROVIRAL THERAPY; ENDOPLASMIC-RETICULUM STRESS; PREVENTING KAPOSIS-SARCOMA; MULTIPLE-MYELOMA CELLS; PHASE-I TRIAL; ETHYL METHANESULFONATE; MYOCARDIAL-INFARCTION; INFECTED PERSONS; RISK Multiple languages Immunology; Infectious Diseases; Virology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27212